Benzinga | Nov 16, 2021 09:21AM EST

ENDRA Life Sciences Announces Two New Patents

ENDRA Life Sciences Inc. (NASDAQ:NDRA), a pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS(r)), announces that the United States Patent and Trademark Office has issued two patents, including U.S. Patent No. 11172829 (the '829 patent) titled "Thermoacoustic Transducer With Integrated Switch," and U.S. Patent No. 11176848 (the '848 patent) titled "Tissue-mimicking Material for A Multi-modality Imaging Phantom."

* The '829 patent relates to a novel system for reducing false signals in thermoacoustic imaging. This patent enables mitigation of radiofrequency energy effects upon the electronic components of the system. ENDRA expects the '829 patent to be effective for all thermoacoustic imaging applications.

* The '848 patent relates to ENDRA's novel phantom for use with different imaging modalities including thermoacoustic imaging, ultrasound imaging and MRI. This patent enables health practitioners to use a single phantom instead of multiple phantoms when calibrating or validating a thermoacoustic system for use. The '848 patent should be particularly valuable as ENDRA proceeds with clinical trials in multiple countries.

"These issued patents -- our 22nd and 23rd in the U.S. -- support our strategy to develop optimized hybrid ultrasound and thermoacoustic imaging systems and to broaden the potential applications for our proprietary TAEUS(r) technology in areas with unmet clinical needs," stated ENDRA's Chief Executive Officer Francois Michelon. "We continue to enhance our intellectual property portfolio to protect our technology in priority global markets. Our portfolio currently stands at 89 assets, which we define as patents issued, filed or in preparation."